Half yearly report to 31 March 2020
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, announces its unaudited interim results for the six months ended 31 March 2020. Financial highlights: · Reported revenues of £4. 6 million; 33. 0% growth on H1 2019 (2019: £3. 4 million) · Strong gross margin at 66. 5% (2019: 66.READ MORE
"As clinical trials become more complex, we're seeing the [use of] medical imaging increasing" says Giulio Cerroni in S&P Global Market Intelligence interview
IXICO has been featured in S&P Global Market Intelligence's recently published article focused on use of AI technology in drug development. The article entitled 'Big Pharma recruits NASA scientist, sets up command centers in AI push' by Etain Lavelle was originally published here.READ MORE
Schizophrenia International Research Society (SIRS) 2020 Poster
Actigraphic Monitoring of Sleep-Wake Cycle in Schizophrenia Outpatients
Receiving a Long-Acting Injectable Antipsychotic: Feasibility and Initial
Results From a Prospective RCT
Alzheimer’s Association International Conference - AAIC
AAIC 2020 will bring together international investigators, clinicians and care researchers to discuss the latest studies, theories and discoveries that will help bring the world closer to breakthroughs in dementia science.READ MORE
Software Validation LeadREAD MORE
IXICO has extensive experience in supporting regulatory-compliant clinical research, working with clients on the selection and use of neuroimaging and digital biomarkers - whether directly with your teams or as part of collaborative consortia.Read more
We have extensive experience in definition and delivery of early phase clinical development, where rigorous patient safety runs hand-in-hand with flexibility around trial design and data analytics.
IXICO's global network of over 2,000 imaging sites across 75 countries and bespoke TrialTracker platform ensure that large-scale trials can be set up quickly and efficiently to deliver data that is as reliable as it is regulatory compliant.Read more
IXICO understands the challenges of extended longitudinal studies, and the importance of monitoring patient safety and drug utilization for ongoing optimization of patient pathways post marketing.Read more
IXICO has supported important Alzheimer's Disease research since 2007 and continues to assist many pharmaceutical companies in their search for novel therapies. We have provided both MRI and PET imaging biomarkers for over 70 clinical studies in neuroscience, of which, over 30 have been in Alzheimer's disease.Read more
IXICO is the leading company for Huntington's disease (HD) specialist imaging. Our neuroscience expertise enables global, regulatory compliant imaging and digital biomarker analytical services for clinical development. We are a trusted imaging provider and preferred supplier for pharma and biotech, with IXICO providing advanced imaging analytics for 11 HD trials.Read more
IXICO first supported a clinical study for PD in 2016 and continue to invest in our technological solutions to support clinical trials in this area. PD is the second most common neurodegenerative disease, after Alzheimer’s disease. An estimated 7 to 10 million people worldwide are living with PD.Read more
We have been involved in MS since 2015 through our Assessa PML collaboration with big pharma. Multiple Sclerosis is a condition that affects the brain and spinal cord. It is the most common autoimmune disorder of the central nervous system, affecting around 2.3 million people globally as of 2015.Read more
Progressive Supranuclear Palsy (PSP) is a Parkinsonian neurological rare condition caused by the premature loss of nerve cells in certain parts of the brain, which leads to difficulties with balance, movement, vision, speech and swallowing. IXICO has supported clinical trials in this area since 2015, providing advanced analytics for 5 clinical trials across 230 global sites.Read more
IXICO specialises in data collection, optimisation, and analytics of rare neurological disorders, including but not limited to Huntington's Disease (HD), Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and Spinocerebellar Ataxia (SCA).Read more
IXICO is at the forefront of the industry in developing and validating unique neuroimaging methods and MRI and PET image analysis techniques, providing more accurate and richer brain structural and functional information.
IXICO is developing and validating new machine learning algorithms to analyse wearable biosensor data for specific neurodegenerative diseases. These disease-specific algorithms can improve the sensitivity and specificity of standard algorithms to measure physiological parameters such as sleep, activity and circadian rhythm.
Analytics & AI
Analytics & AI
In neuroscience, AI has applications across the spectrum of understanding and treating the disease. IXICO provides sophisticated AI technology to support clinical development programmes in interpreting complex patient data.
IXICO's compliant image and digital data management, provides all you need to manage the complex data workflows that come with many clinical trials. IXICO also offers a secure online digital platform as an enabler of clinical decision support for patient selection and post-marketing surveillance.